Fortrea (NASDAQ:FTRE – Get Free Report) had its price objective lowered by investment analysts at Barclays from $25.00 to $12 ...
Fortrea (NASDAQ:FTRE – Get Free Report) had its target price decreased by analysts at The Goldman Sachs Group from $22.00 to ...
Clinical research company Fortrea Holdings (NASDAQ:FTRE) missed Wall Street’s revenue expectations in Q4 CY2024, with sales ...
Q4 2024 Earnings Call Transcript March 3, 2025 Fortrea Holdings Inc. misses on earnings expectations. Reported EPS is $0.18 ...
Fortrea (NASDAQ:FTRE – Free Report) had its target price lowered by Evercore ISI from $20.00 to $15.00 in a research report sent to investors on Tuesday morning,Benzinga reports. The firm currently ...
StockStory.org on MSN3d
Why Fortrea (FTRE) Shares Are Plunging TodayShares of clinical research company Fortrea Holdings (NASDAQ:FTRE) fell 18.5% in the pre-market session after the company ...
Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) shares gapped down before the market opened on Monday after the company announced weaker than expected quarterly earnings. The stock had ...
Hosted on MSN1d
Spotting Winners: Charles River Laboratories (NYSE:CRL) And Drug Development Inputs & Services Stocks In Q4Looking back on drug development inputs & services stocks’ Q4 earnings, we examine this quarter’s best and worst performers, ...
Hosted on MSN4d
What To Expect From Fortrea’s (FTRE) Q4 EarningsClinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what ...
FORTREA ($FTRE) posted quarterly earnings results on Monday, March 3rd. The company reported earnings of $0.18 per share, missing estimates of $0.37 by $0.19. The ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback